Helena Laboratories Corporation

Helena Laboratories Corporation, headquartered in Beaumont, Texas, manufactures electrophoresis analyzers, reagents, consumables, and clinical laboratory diagnostic equipment sold as a prime contractor exclusively to the federal government, competing full-and-open without set-aside designation on the vast majority of its portfolio. The company is a for-profit manufacturer with a named subsidiary, Labcon North America, and operates across 769 prime federal awards spanning the past forty-seven years, with recent activity running at four to ten awards annually since 2022.

Helena Laboratories' customer concentration is heavily concentrated within the Veterans Affairs system, which accounts for the overwhelming majority of its federal business. The top customer by potential value, Veterans Integrated Service Network 21, anchors $4.4 million across eleven awards; VISN 20 carries $4.1 million across three awards; and VISN 4, VISN 10, and VISN 17 round out the top tier at $1.6 million, $1.5 million, and $1.4 million respectively. These five VISNs alone represent 79 percent of the combined potential value across all awards. Department of the Army and Department of the Navy Bureau of Medicine and Surgery appear in the next tier with eighteen and seventeen awards respectively. Helena Laboratories' award footprint spans twenty-six distinct customer agencies, but the VA network dominates both by count and dollars.

Helena Laboratories holds position on multiple IDIQs and blanket purchase agreements across the VA system. The top parent vehicle by task-order count, Indefinite Delivery Contract V673P5492, carries fifty-six task orders with $207 thousand combined potential value; Indefinite Delivery Contract V603P3419 carries sixteen task orders with $216 thousand. Recent named vehicles include a $3.775 million BPA with VISN 20 for electrophoresis kits, equipment, and maintenance and repair services awarded February 1, 2026 (set-aside as total small business under NAICS 325413, not representative of Helena's full footprint); a $500 thousand single-award IDIQ with VISN 10 for electrophoresis testing services, equipment, and supplies through July 31, 2030; a $670 thousand single-award IDC with VISN 2 for electrophoresis testing services supporting Albany, Buffalo, and Syracuse VA medical centers through March 31, 2030; a $725 thousand single-award IDIQ with VISN 17 for CTX electrophoresis analyzers and reagents through November 30, 2028; and a $241 thousand BPA with VISN 19 for electrophoresis urine and serum kits through July 31, 2029. The $3.775 million VISN 20 BPA supports the Western States Network Consortium covering VISNs 17, 19, 20, 21, and 22 across facilities in Dallas, San Antonio, Temple, Denver, Portland, and San Francisco.

Recent representative delivery orders and purchase orders illustrate Helena's capability portfolio: a $71 thousand delivery order from VISN 10 in August 2026 for electrophoresis clinical laboratory equipment, reagents, and services; a $49 thousand BPA call from VISN 19 in August 2026 for electrophoresis urine and serum kits; a $37 thousand delivery order from VISN 17 in December 2025 for electrophoresis immunofixation products; a $140 thousand delivery order from VISN 17 in December 2025 for CTX electrophoresis analyzer and reagents; a $330 thousand total small business set-aside purchase order from VISN 4 in February 2023 for laboratory supplies and reagents supporting electrophoresis testing at Pittsburgh VA Medical Center through February 2028; and a $133 thousand total small business set-aside purchase order from VISN 21 in February 2022 for electrophoresis capabilities and equipment through September 2025. Helena's work across the VA spans automated agarose gel electrophoresis analyzers, capillary electrophoresis instruments, serum and urine protein electrophoresis kits, immunofixation testing consumables, and maintenance and repair services. The company also serves the Defense Health Agency and Department of the Army on laboratory equipment and maintenance orders in the tens of thousands of dollars.

Helena Laboratories' product-category concentration reflects its specialized focus: in-vitro diagnostic substance manufacturing accounts for 101 of the 769 awards; analytical laboratory instrument manufacturing for fifty-eight; drugs and druggists' sundries merchant wholesalers for seventeen; and other electronic and precision equipment repair and maintenance for ten. By PSC, laboratory equipment and supplies comprise 358 awards; in vitro diagnostic substances, reagents, test kits and sets comprise 213; and medical and surgical instruments, equipment, and supplies comprise seventy-one.

Activity has been stable to slightly growing over the past five years, with between four and ten awards annually (2022: seven, 2023: nine, 2024: six, 2025: ten, 2026: four through early August). Nine awards with a combined potential value of $940 thousand face ultimate completion within the next twenty-four months, representing recompete exposure on that dollar value. Helena's combined potential value across all recent awards is $16.4 million, with $6.2 million (38 percent) obligated to date. The company operates as a sole prime on all tracked awards with no subcontract footprint in federal records, indicating a direct-to-customer model across the VA and Department of Defense medical systems.